Silodosin Capsules 4?mg ×?28 Capsules

Silodosin Capsules 4?mg ×?28 Capsules

$2.00

Silodosin is a highly selective ??A?adrenergic receptor antagonist designed to relax smooth muscle in the prostate and bladder neck. These 4?mg capsules, supplied in a 2?×?14?capsule pack by Hainan Wanwei Pharmaceutical, are intended exclusively for laboratory and preclinical research use, such as urological, cardiovascular, and receptor pharmacology studies. Not approved for clinical, diagnostic, therapeutic, or veterinary applications.

EMI starting from $0.00/month - View Plans
Compare
分类:

描述

Product Specifications

Attribute Details
Product Name Silodosin Capsules
Generic Name Silodosin
CAS Number 160970?54?7
Molecular Formula C??H??F?N?O?
Molecular Weight ~495.5?g/mol
Dosage Form Oral gelatin capsule
Strength 4?mg per capsule
Pack Size 4?mg ×?14 capsules ×?2 blisters per box
Approval Number China NMPA H20213639
Product Code 86982249000037
Manufacturer Hainan Wanwei Pharmaceutical Co., Ltd.
Barcode (not provided)
Storage Conditions Store at 15?25?°C; protect from light
Intended Use Laboratory and preclinical research only

Mechanism of Action

Silodosin is a highly selective ??A?adrenergic receptor antagonist that relaxes prostate, bladder neck, and urethral smooth muscle, enhancing urinary flow. It has a >500?fold selectivity for ??A over ??B receptors, minimizing systemic hypotension sciencedirect.com+15selleckchem.com+15pubmed.ncbi.nlm.nih.gov+15.


Research Applications & Pharmacology

Benign Prostatic Hyperplasia (BPH):

  • Employed in preclinical models to study symptomatic relief via smooth muscle relaxation .

Urological & Cardiovascular Research:

  • Enables exploration of urinary symptomatology with minimal cardiovascular side effects, a desirable profile in cardiovascular-sensitive studies pubmed.ncbi.nlm.nih.gov.

Receptor Pharmacology:

  • Used in vitro and ex vivo assays to evaluate ??A antagonism. Notably, it shows high affinity (Ki ~0.036?nM) and effectively inhibits receptor-mediated contractions across species .

Pharmacokinetics:

  • Orally bioavailable (~32%), protein binding ~96.6%, metabolized via UGT2B7 and CYP3A4, half-life ~13?±?8?h, excreted ~34% unabsorbed renally and ~55% fecally .


Safety Profile & Handling

  • Cardiovascular Effects: Selectivity for ??A minimizes blood pressure changes; no QT prolongation observed .

  • Common Adverse Events: Dizziness, orthostatic hypotension, dry eyes/mouth, diarrhea, headaches, and retrograde ejaculation.

  • Hepatic & Renal Cautions: Dose adjustments recommended in moderate renal impairment; contraindicated in severe renal/liver dysfunction.

  • Drug Interactions: Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) .

  • Handling: Use standard lab PPE, store in a controlled environment, and dispose of per biosafety guidelines.

其他信息

重量 1 公斤
尺寸 18 × 16 × 18 厘米

评价

目前还没有评价

成为第一个“Silodosin Capsules 4?mg ×?28 Capsules” 的评价者

您的邮箱地址不会被公开。 必填项已用 * 标注

EMI Options

Select at least 2 products
to compare